Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

(2018) Martin O. Weickert et al.   CLINICAL THERAPEUTICS

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

(2018) Marianne Pavel et al.   ENDOCRINE-RELATED CANCER

Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension

(2018) Pashtoon Murtaza Kasi   PANCREAS

Peripheral Serotonin Synthesis as a New Drug Target

(2018) Susann Matthes et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Developments in the treatment of carcinoid syndrome – impact of telotristat

(2018) David L Chan et al.   Therapeutics and Clinical Risk Management

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

(2017) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Carcinoid Syndrome Impact Survey: Evaluation of the burden of illness and the gap between patient and oncologist perceptions.

(2017) Grace Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

(2017) Jonathan R. Strosberg et al.   PANCREAS

A Budget Impact Model of The Addition of Telotristat Ethyl Treatment In Patients With Uncontrolled Carcinoid Syndrome

(2017) K Fust et al.   VALUE IN HEALTH

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms

(2017) Krystallenia I. Alexandraki et al.   Biomed Research International

Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs

(2017) V. N. Joish et al.   JOURNAL OF MEDICAL ECONOMICS

Refractory carcinoid syndrome: a review of treatment options

(2016) Rachel P. Riechelmann et al.   Therapeutic Advances in Medical Oncology

Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation

(2015) Janice J. Kim et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial

(2015) Marianne Pavel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

(2014) Julie Hallet et al.   CANCER

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

(2014) M. H. Kulke et al.   ENDOCRINE-RELATED CANCER

Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine

(2013) Kara Gross Margolis et al.   GUT

Comparison of Health-Related Quality of Life in Patients With Neuroendocrine Tumors With Quality of Life in the General US Population

(2011) Jennifer L. Beaumont et al.   PANCREAS

Discovery and Characterization of Novel Tryptophan Hydroxylase Inhibitors That Selectively Inhibit Serotonin Synthesis in the Gastrointestinal Tract

(2008) Q. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS